VolitionRX’s Promising Growth: Buy Rating Backed by Revenue Surge and Strategic Partnerships

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on VolitionRX (VNRX – Research Report) and keeping the price target at $2.50.

Yi Chen has given his Buy rating due to a combination of factors that highlight VolitionRX’s promising growth prospects. The company reported a 44% year-over-year revenue increase in the first quarter of 2025, aligning with projections, and has begun generating revenue from its CE-Marked Nu.Q NETs automated product in Europe. This product is being evaluated by multiple hospital networks, with further evaluations expected to commence later in the year, potentially leading to its integration into routine clinical practice by 2026.
Additionally, VolitionRX is in confidential talks with several international companies regarding licensing and supply agreements for its Nu.Q NETs assay, which could significantly boost revenue in the latter half of 2025. The company’s strengthened cash position, bolstered by a convertible loan note, provides sufficient capital for near-term operations, supporting its business model focused on licensing revenue. The valuation of the company, based on a discounted cash flow model, suggests a favorable price target, though risks such as clinical development failures and market traction challenges remain.

Based on the recent corporate insider activity of 88 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VNRX in relation to earlier this year.